XML 24 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Operating activities    
Consolidated net loss $ (30,643) $ (65,003)
Adjustments to reconcile consolidated net loss to net cash used in operating activities    
Depreciation and amortization 288 225
Loss (gain) on sale of property and equipment 81 (27)
Net unrealized gain on investments - Hedge Funds (63)
Realized loss on investment in equity securities 46
Realized gain on available-for-sale securities (178) (1,772)
Amortization of discount on available-for-sale securities (285) (1,891)
Loss on initial investment in Day Three upon acquisition 1,633
Loss on impairment of goodwill 3,050
Realized gain on equity investments - Cyclo (424)
Unrealized loss (gain) on equity investments - Cyclo 5,144 (37)
Recovery of receivables from Cornerstone (31,305)
In-process research and development expense 89,861
Unrealized loss (gain) on convertible notes receivable, due from Cyclo 719 (1,191)
Gain on dissolution of a business 18
Equity in loss of Day Three 422
Change in deferred income taxes (165)
Credit loss expense 20
Stock-based compensation 2,123 2,296
Gain on DTLM Sale Transactions (30)
Change in assets and liabilities, net of effects from acquisitions:    
Trade accounts receivable (151) (150)
Interest receivable 515 (139)
Inventory (11)
Prepaid expenses and other current assets 818 673
Prepaid clinical costs (current and non-current) 112
Other receivables (273)
Other assets 28 22
Accounts payable and accrued expenses (922) (146)
Other current liabilities (67) (938)
Due to related parties (10) 138
Accrued expenses, noncurrent 913
Convertible notes payable 5
Other liabilities 15 (70)
Net cash used in operating activities (18,924) (7,802)
Investing activities    
Purchase of property and equipment (4) (143)
Proceeds from sale of property and equipment 13
Purchases of available-for-sale securities (16,988) (155,657)
Proceeds from the sale and maturities of available-for-sale securities 80,694 153,352
Proceeds from Day Three patent sale 270
Purchase of intangible assets (17) (35)
Proceeds from sales of equity securities 271
Issuance of Convertible notes receivable, due from Cyclo (4,000)
Payments for Convertible notes receivable, due from Cyclo (19,500)
Purchase of investments in Cyclo (6,786)
Issuance of convertible note receivable (1,000)
Issuance of Day Three Promissory Notes (1,989)
Proceeds from investments - Other Pharmaceuticals 42
Cash paid in Cyclo Merger, net of cash acquired (2,709)
Cash acquired in acquisition of Day Three, net of cash payments 1,099
Cash acquired in the Cornerstone Acquisition, net of cash payments 1,256
Proceeds from hedge funds 2,547 2,500
Net cash provided by (used in) investing activities 44,035 (10,820)
Financing activities    
Principal payments on installment note payable (800)
Payments for taxes related to shares withheld for employee taxes (215) (136)
Purchases of treasury stock (168)
Proceeds from issuance of common stock in Rights Offering, net of transaction costs 25,001
Proceeds from sale of Rafael Medical Devices membership units 44 925
Net cash provided by (used in) financing activities 24,830 (179)
Effect of exchange rate changes on cash and cash equivalents 153 (22)
Net increase (decrease) in cash and cash equivalents 50,094 (18,823)
Cash and cash equivalents, beginning of year 2,675 21,498
Cash and cash equivalents, end of year 52,769 2,675
Non-cash supplemental disclosure    
Fair value of Class B common stock issued as consideration in Cyclo Merger 14,692
Fair value of Rollover Options issued as consideration in Cyclo Merger 360
Fair value of Replacement Warrants issued as consideration in Cyclo Merger 472
Fair value of Cyclo Convertible notes receivable included as consideration in Cyclo Merger 21,472
Transaction costs related to the Rights Offering included in accounts payable 94
Conversion of RFL Line of Credit into Cornerstone Common Stock 37,845
Conversion of 2023 Promissory Note into Cornerstone Common Stock 2,663
Recognition of noncontrolling interest in the Cornerstone Acquisition 27,501
Recognition of noncontrolling interest in the RP Finance Consolidation, net of elimination 9,585
Gain on RP Finance Consolidation recorded as an adjustment to additional paid-in capital due to related party nature of transaction, net of elimination 5,751
Non-cash consideration received in exchange for equipment 34
Conversion of Convertible notes receivable, due from Cyclo into common stock 2,500
Elimination of principal and accrued interest on the Day Three Promissory Notes included in consideration for acquisition of Day Three 2,000
Convertible note receivable received in exchange for Day Three Labs Manufacturing assets $ 500